Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Receives $51.59 Consensus Price Target from Analysts

Shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) have been assigned a consensus rating of “Moderate Buy” from the ten brokerages that are presently covering the company, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $51.5857.

A number of research analysts recently commented on ZLAB shares. UBS Group began coverage on Zai Lab in a research report on Wednesday, January 7th. They issued a “buy” rating and a $35.00 price target on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Zai Lab in a report on Wednesday, January 21st. JPMorgan Chase & Co. dropped their target price on shares of Zai Lab from $46.00 to $39.00 and set an “overweight” rating for the company in a research report on Thursday, February 5th. Jefferies Financial Group raised shares of Zai Lab to a “strong-buy” rating in a report on Monday, January 19th. Finally, Zacks Research cut shares of Zai Lab from a “hold” rating to a “strong sell” rating in a research note on Friday, January 23rd.

Zai Lab Price Performance

Shares of NASDAQ:ZLAB opened at $18.77 on Tuesday. The company has a market capitalization of $2.10 billion, a P/E ratio of -9.63 and a beta of 0.88. The business’s 50 day simple moving average is $18.05 and its 200 day simple moving average is $25.66. Zai Lab has a 1 year low of $15.96 and a 1 year high of $44.34.

Insider Buying and Selling at Zai Lab

In other news, insider Rafael Amado sold 10,787 shares of Zai Lab stock in a transaction on Wednesday, December 31st. The stock was sold at an average price of $17.43, for a total value of $188,017.41. Following the transaction, the insider owned 52,391 shares in the company, valued at approximately $913,175.13. This trade represents a 17.07% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 4.96% of the company’s stock.

Institutional Trading of Zai Lab

An institutional investor recently raised its position in Zai Lab stock. SG Americas Securities LLC grew its holdings in shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) by 6.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 10,396 shares of the company’s stock after acquiring an additional 642 shares during the quarter. SG Americas Securities LLC’s holdings in Zai Lab were worth $183,000 at the end of the most recent quarter. Institutional investors own 41.65% of the company’s stock.

About Zai Lab

Zai Lab Ltd (NASDAQ: ZLAB) is a biopharmaceutical company focused on the research, development, manufacturing and commercialization of innovative therapies. Headquartered in Shanghai, China, Zai Lab operates R&D centers in Asia and the United States and maintains commercial offices across Greater China, North America, Europe and Australia. The company’s end-to-end platform encompasses discovery biology, translational development, clinical research and global supply chain management.

The company’s marketed portfolio is anchored by Brukinsa (zanubrutinib), a next-generation Bruton’s tyrosine kinase inhibitor approved for several B-cell malignancies.